Covid: Both vaccines get final nod, first shots to be of Covishield
Monday, 4 January 2021 The Serum Institute of India’s Covishield is likely to be first shot used in India’s vaccine drive against Covid-19. For Covaxin, the authorisation is in clinical-trial mode, which means that monitoring of recipients will be in the same mode as those taking the trial. Vaccination is likely to be launched simultaneously in most states that were part of the January 2 dry run.
Madhya Pradesh Chief Minister Shivraj Singh Chouhan on January 04 said that he will not get vaccinated against COVID-19 for now, as he wants the priority groups to be served first. "I have decided that I will not get vaccinated for now, first it should be administered to others. My turn should come...
Prime Minister Narendra Modi said Covid-19 vaccination was being done for free at government hospitals. PM Modi was addressing Janaushadhi Diwas celebrations via video conferencing. “We are proud of our scientists for we now have ‘Made in India’ vaccine for us and the rest of the world. Covid-19 vaccination is being done for free at government hospitals in India. Covid-19 vaccine costs Rs 250 in private hospitals which is the cheapest in world. Even I got my first dose of Covid-19.” PM Modi added, “1.5 lakh health and wellness centre are being made in villages out of which 50,000 have already started functioning. These centres will be equipped to tackle serious health issues.” Watch the full video for more.
Credit: HT Digital Content Duration: 02:15Published
Prime Minister Narendra Modi inaugurated 7500th Janaushadhi Kendra at North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS) in Shillong. The event took place via video conferencing on March 07. While addressing the event, PM Modi said, "Today, we have 'Made in India' vaccines for our country and for the world. COVID-19 vaccination is being done for free at government hospitals and at the cost of Rs 250 at private hospitals. I have also taken the first dose of the COVID-19 vaccine."
As per the data released by Ministry of Health and Family Welfare (MoHFW), India on March 07 reported single-day spike of 18,711 new coronavirus cases in the last 24 hours. 100 deaths in the same period pushed the COVID-19 toll in the country to 1,57,756. India's confirmed cases of coronavirus stand at 1,12,10,799 which include 1,84,523 active infections. More than 1,08,68,520 people have recovered from the virus with 14,392 new discharges in last 24 hours. Till date the total vaccination is 2,09,22,344. According to Indian Council of Medical Research (ICMR), a total of 7,37,830 samples were tested on March 06. Cumulative samples tested for COVID-19 till March 06 are 22,14,30,507.
A technical committee of experts in Mexico gave a unanimous favorable opinion Friday on approving the Covaxin vaccine made by the Indian pharmaceutical company.. IndiaTimes
The phase 3 results of Covaxin released on Wednesday showing 81% efficacy is seen by the government as a major validation of the scientific process and.. IndiaTimes
The second phase of India's covid vaccine drive is receiving an enthusiastic response. However, if you are hesitant about the vaccine since you are on medication or recently recovered from some serious illness or even Covid-19 for that matter, you may have some questions that we address in this video.
#Covaxin #Covishield #CovidVaccine
The EU's medicines regulator has approved use of Moderna's Covid-19 vaccine, marking the shot's second green light from authorities following approval in the U.S. Julian Satterthwaite reports.
Amid the criticism of the Drug Controller General of India (DCGI) for granting approval for emergency use of Covid-19 vaccine Covaxin, its manufacturer Bharat... Mid-Day Also reported by •IndiaTimes
Vaccine maker Bharat Biotech on Tuesday said it has inked an agreement with Brazil’s Precisa Medicamentos for distribution of India’s first indigenous... IndiaTimes
In the backdrop of the Covid-19 vaccine rollout in the country, senior Congress leader Manish Tewari on Saturday raised questions over the emergency use approval... IndiaTimes